Emergent BioSolutions Inc.

NYSE:EBS

Biotechnology

Healthcare
$5.50 -2.58%

-$0.21 today

Market cap
$282.78M
Beta
2.33
P/E (TTM)
-47.9
EPS (TTM)
-$0.17
52W Low $5.62High $14.06

Volume 0.82M

Average 0.78M

EBS EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Emergent BioSolutions Inc.NYSE: EBS

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA dips below year-ago levels

Q1 FY2026 EBITDA of $48.5M fell 63.6% year over year, behind the +28.1% change in trailing-twelve-month EBITDA. Over 3 fiscal years it compounded at +148.3% a year.

Context

  • EBITDA amounted to 32.4% of revenue in FY2025, up 27.2 pp from a year earlier.
  • EBITDA increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 2 analysts of $175.67M (-26.9%) for the fiscal year ending Dec 2026, a slowdown from the +350.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$48.5M+488.0% QoQ
Last fiscal yearDec 2025
$240.4M+350.2% YoY
LTMMar 2026
$154.5M+28.1% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.6%+35.3%+99.0 pp
1 year+350.2%-26.9%-377.1 pp
3-year CAGR+148.3%+0.7%-147.7 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
240.4M USD
Year-over-year change
+350.2%
4-year CAGR
-16.9%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How EBS compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +28.1% is the 6th highest of 11, against a peer median of +16.3%.
  • EBITDA amounts to 22.8% of revenue for EBS, versus a peer median of 29.3%.
EBS Competitors
EBITDA for EBS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EBSEmergent BioSolutions Inc.LTM Mar 2026$154.5M USD+28.1%+148.3%22.8%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$131.28M USD+170.9%—43.8%
SNDLSNDL Inc.LTM Mar 2026CA$49.42M CAD+201.3%—5.3%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$39.9M USD+145.1%—9.5%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$37.31M USD+1061.2%+22.4%7.3%
SIGASIGA Technologies, Inc.LTM Mar 2026$27.5M USD-56.2%-11.5%29.3%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$42.27M USD-2.3%——
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$51.63M USD-40.6%—102.7%
PRTAProthena Corporation plcLTM Mar 2026-$74.72M USD+35.0%—129.0%
CMPSCOMPASS Pathways plcLTM Mar 2026-$176.6M USD-34.4%——
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$184.67M USD-43.8%——
Peer median (excluding EBS) —+16.3%+5.4%29.3%

Competitors are the stored peer set for EBS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.77B1.12B1.05B1.04B742.9M
Cost of Revenue980.4M644.5M689.3M668.2M392.3M
Gross Profit793.2M473M360M375.4M350.6M
Gross Margin44.7%42.3%34.3%36.0%47.2%
Research & Development235.2M188.3M111.4M70.7M53.8M
Selling, General & Admin348.7M339.5M356.7M298.7M186.6M
Operating Expenses451.8M643M1.09B484.1M240.4M
Depreciation & Amortization118.2M125M121.1M105.6M98.3M
EBITDA504.2M15.7M(47M)53.4M240.4M
EBITDA Margin28.4%1.4%-4.5%5.1%32.4%
Operating Income341.4M(170M)(726.4M)(108.7M)110.2M
Operating Margin19.2%-15.2%-69.2%-10.4%14.8%
Interest Income00000
Interest Expense34.5M37.3M87.9M71M59.3M
Other Income / Expenses(38.2M)(49M)(4.8M)(34.2M)(27.4M)
Income Before Tax303.2M(219M)(731.2M)(142.9M)82.8M
Pre-Tax Margin17.1%-19.6%-69.7%-13.7%11.1%
Income Tax Expense83.7M(7.4M)29.3M47.7M30.2M
Net Income219.5M(211.6M)(760.5M)(190.6M)52.6M
Net Margin12.4%-18.9%-72.5%-18.3%7.1%
EPS (Basic)4.10(4.22)(14.85)(3.60)0.98
EPS (Diluted)4.06(4.22)(14.85)(3.60)0.93
Weighted Avg Shares53.5M50.1M51.2M53M53.5M
Weighted Avg Shares (Diluted)54.1M50.1M51.2M53M56.7M

Emergent BioSolutions Inc.

NYSE:EBS

Intrinsic Alpha fair value

Locked

Current Price

$5.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.